Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab

Resultado de la investigación: Contribución a una revistaArtículo

Idioma originalInglés estadounidense
Páginas (desde-hasta)665-676 
Número de páginas12
PublicaciónCurrent Drug Targets
Volumen17
DOI
EstadoPublicada - 1 ene 2016

Citar esto

@article{daeba11dc1c949519f3144f2e7a0c2e7,
title = "Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab",
author = "{MORENO FR{\'I}AS}, ERNESTO",
year = "2016",
month = "1",
day = "1",
doi = "10.2174/1389450117666160201114308 ",
language = "American English",
volume = "17",
pages = "665--676 ",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",

}

Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab. / MORENO FRÍAS, ERNESTO.

En: Current Drug Targets, Vol. 17, 01.01.2016, p. 665-676 .

Resultado de la investigación: Contribución a una revistaArtículo

TY - JOUR

T1 - Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab

AU - MORENO FRÍAS, ERNESTO

PY - 2016/1/1

Y1 - 2016/1/1

U2 - 10.2174/1389450117666160201114308 

DO - 10.2174/1389450117666160201114308 

M3 - Article

VL - 17

SP - 665-676 

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

ER -